Trial Profile

Relative Bioavailability of Nintedanib Given Alone and in Combination With Ketoconazole at Steady State in Healthy Male Volunteers (an Open-label, Randomised, Two-way Cross-over Clinical Phase I Study)

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Mar 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nintedanib (Primary) ; Ketoconazole
Indications Colorectal cancer; Fallopian tube cancer; Liver cancer; Mycoses; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cancer; Solid tumours
Focus Pharmacokinetics
Sponsors Boehringer Ingelheim Pharmaceuticals

02 Mar 2018 Results investigating the effects of ketoconazole, a p-glycoprotein inhibitor, and rifampicin, a p-glycoprotein inducer, on the pharmacokinetics of nintedanib from 2 trials (NCT01679613, NCT01770392) published in the European Journal of Drug Metabolism and Pharmacokinetics
01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
12 Sep 2012 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com